Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Genfit S.A. GNFT.PA
$3.75
-$0.05 (-1.32%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
189373000.00000000
-
week52high
4.77
-
week52low
2.98
-
Revenue
20195000
-
P/E TTM
-8
-
Beta
0.93091600
-
EPS
-0.55000000
-
Last Dividend
0.00000000
-
Next Earnings Date
14 апр 2023 г. в 12:00
Описание компании
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 05 апр 2021 г. |
| Stifel | Buy | Hold | 23 июл 2020 г. |
| B of A Securities | Underperform | 25 июн 2020 г. | |
| SVB Leerink | Outperform | Outperform | 12 мая 2020 г. |
| HC Wainwright & Co. | Neutral | Buy | 12 мая 2020 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии